BREAKING: The Supreme Court Just Handed Bayer a Lifeline. Here Is What Plaintiff Lawyers Need to Do Right Now
- Michael Stanisci
- Jun 25
- 8 min read
Today, June 25, 2026, the Supreme Court decided Monsanto v. Durnell 7-2. Justice Brett Kavanaugh wrote the majority opinion, holding that FIFRA expressly preempts state-law failure-to-warn claims against Monsanto for not putting a cancer warning on Roundup.
Let me tell you what that really means, why it happened, and where we can go from here. Much smarter lawyers and individuals than me are thankfully at the helm, so more information will emerge on strategy that I'm certain the teams are more than prepared for. This is purely an opinion and observation that might help guide your thoughts.
The Story
John Durnell was a gardener. He used Roundup for years. He got non-Hodgkin's lymphoma. A St. Louis jury awarded him $1.25 million on a failure-to-warn claim. Missouri courts upheld it.
Bayer took it to the Supreme Court and asked one question. Does federal pesticide law, FIFRA, block state-law failure-to-warn claims when the EPA has not required the warning?
Today, seven justices said yes.
The majority leaned hard on one core idea. After EPA approves a pesticide's label at registration, manufacturers are legally required to use that label unless and until EPA approves or requires a change. Durnell's state tort claim would require Monsanto to add a cancer warning, which is "in addition to" and "different from" what federal law requires. FIFRA's preemption clause therefore blocks it. That is the holding, straight from the opinion text.
The Court also drew directly from Riegel v. Medtronic. The majority opinion states explicitly that Riegel "further confirms" that the failure-to-warn claim is expressly preempted, calling FIFRA's preemption clause and the Medical Device Amendments clause "nearly identical," and concluding: "Riegel is dispositive here." That is not analysis or commentary. Those are the Court's own words. I will come back to why this matters.
The Dissent: Who Said No and Why
Justice Ketanji Brown Jackson filed a dissenting opinion joined by Justice Neil Gorsuch. Jackson argued the majority misunderstood FIFRA's requirements and misinterpreted the scope of its preemption, and she said the ruling leaves Durnell without a remedy for significant harms he actually suffered.
Gorsuch joining Jackson is not a typo. At oral argument, Roberts and Gorsuch had joined Jackson in pushing back hard on Bayer's theory that states cannot pursue pesticide manufacturers in the same way EPA can. Gorsuch ended up in dissent anyway.
Now about Kagan. Some observers were surprised she joined the majority.
To be clear, this is my read of the context, not a finding of the Court. At oral argument, Kagan questioned Durnell's lawyer directly about how allowing state-level challenges squared with FIFRA's uniformity provision, which she called "clearly designed to achieve uniformity in labeling." Kagan also joined Alito in questioning whether Loper Bright, the 2024 case that ended agency deference, was truly relevant to this dispute. Her questions during argument signaled skepticism of the plaintiff's position. The final vote reflects that. She was not switching sides so much as following the logic of the statutory text and uniformity all the way through.
What Claims Are Affected and What Path Remains
Here is the most important thing for plaintiff lawyers to understand right now. And I am going to be straight with you, because you deserve the full picture, not just the hopeful one.
Failure-to-warn claims tied to label content are gone. That is the holding. If your entire theory rests on Monsanto failing to put a cancer warning on the label, and the EPA did not require that warning, the Supreme Court closed that door today.
Now let us talk about what comes next. And why it is harder than it sounds.
Path One: Design Defect
Design defect is the most-discussed alternative. Here is what you actually need to prove it.
A design defect claim argues that glyphosate itself is unreasonably dangerous in its chemical formulation, regardless of what any label says. Not that the warning was missing. That the product, as designed, should not have been sold.
Two warnings before you go down this road.
First, in the actual Durnell trial, the same jury that awarded Durnell $1.25 million on failure to warn found for Monsanto on the strict liability defective design claim. Design defect lost at the same trial where failure to warn won. That is the real record. It is not a theoretical risk. Juries have already rejected this theory on similar facts.
Second, courts may view a design defect claim as a failure-to-warn claim in disguise if the theory still centers on what Monsanto knew and did not disclose. If your design defect case is really about the missing cancer warning wearing a different legal coat, Bayer's lawyers will say so, and some courts will agree. You need the theory to stand on its own legs, arguing that the product's chemical composition was itself unreasonably dangerous regardless of any label.
Bates v. Dow Agrosciences (2005) remains controlling law that design defect claims are not preempted by FIFRA, and Monsanto conceded this at oral argument. That is real. But surviving preemption is only the first hurdle. Winning at trial on that theory is the second, and harder, one.
Path Two: Negligence
Pure negligence claims face the same problem in a different frame. The negligent conduct plaintiff lawyers typically point to, Monsanto's internal suppression of cancer research, the Monsanto Papers, the ghostwritten studies, is compelling. Monsanto's internal corporate communications revealed evidence the company used deceptive tactics to suppress science and relationships with regulators to hide Roundup's cancer links for years. That evidence does not disappear today.
But here is the challenge. If your negligence theory requires a jury to conclude Monsanto should have warned differently, you are back in label territory, and Bayer will argue preemption. A negligence claim that survives today's ruling needs to focus on the conduct itself, what Monsanto knew, what it actively concealed, what it did to mislead regulators, independent of what the label said. That is a narrower target. It requires precise pleading and strong internal documents. The Monsanto Papers give you the raw material. Using them correctly after today requires care.
Path Three: Petition EPA Directly
This is underused and underappreciated. FIFRA preserves the right of any citizen or organization to petition the EPA to modify, suspend, or cancel a pesticide registration. If new science supports a cancer finding, that petition process is available. One legal commentator noted that EPA cancellation proceedings may emerge as a more prominent route for expressing concern over pesticide safety after today's ruling. That is a long road, but it is a road that puts pressure on the regulatory record in a way that could eventually restore the warning claim pathway if the EPA changes its position.
The honest summary on state versus federal
Today's ruling hands the EPA the last word on pesticide warning labels. State juries no longer have a seat at that table on label-based claims. What state courts still control is the design of the product itself and the conduct of the company, when you can prove both without resting the theory on what the label said or failed to say. That is a harder case. It requires better experts, cleaner facts, and more careful pleading. It is not impossible. It is just genuinely harder than the path that closed today.
Watch the Senate. Watch the EPA. And build your cases on facts that survive without a label theory at the center.
What This Means for PMA Preemption
This is my opinion and analysis, not a holding of the Court. But it matters.
The majority drew an explicit parallel between FIFRA's preemption clause and the Medical Device Amendments preemption clause, calling them "nearly identical" and citing Riegel v. Medtronic as dispositive. The logic the Court used here, that federal agency approval of a label constitutes a "requirement" that preempts state tort law demanding something different, is the same logic that has governed Class III medical device PMA preemption for years.
This ruling does not expand PMA preemption. It does reaffirm the framework Riegel established and applies it to a new context. For attorneys working medical device cases, today's ruling is a reminder that the parallel claims doctrine and design defect theories remain the viable path when federal approval creates a preemption shield on warning claims.
The Paraquat Problem
This section is my opinion and prediction, not established fact.
The Roundup preemption ruling will have direct consequences for the paraquat MDL. Syngenta had already filed motions asking courts to dismiss state failure-to-warn claims using the same FIFRA preemption arguments. A Supreme Court ruling for Monsanto provides strong authority for dismissing similar labeling claims in the paraquat litigation.
It is my view that paraquat plaintiff leadership will need to pivot quickly to design defect theories and any claims that do not rest solely on label-based warnings. That is not a guarantee of success. It is where the door is still open.
The Legislative Track
Congress is not done with this issue. The House Farm Bill included a provision that would have codified nationwide label uniformity by statute, which would have done legislatively what Bayer sought in court. The House removed that provision and passed the bill, sending it to the Senate. Watch the Senate closely. The legislative track runs in both directions, and a future Congress could also restore the right that the Court eliminated today.
What Plaintiff Lawyers Should Do Right Now
Audit every Roundup and pesticide file you have. Identify which claims are failure-to-warn only and which include design defect. The design defect path, while not guaranteed, was not closed by today's ruling.
For paraquat cases, meet with co-counsel this week. The Durnell ruling will be cited in pending preemption motions immediately.
Look at the class action settlement in Missouri state court. A state judge granted preliminary approval in March and a final approval hearing is set for early July. Today's ruling strengthens Bayer's hand in cases outside the settlement but does not affect cases already inside it.
Watch Congress. The Senate still has the Farm Bill. The legislative track is alive.
For all pesticide cases going forward, the first question in your intake must be whether the client used the product before reformulation, whether a design defect theory is viable, and whether any non-warning claims can be stated.
From Michael
This ruling is a significant blow. I will not sugarcoat it.
It does not end Roundup litigation entirely. It closes the most common door. Plaintiff lawyers still have a path. It is narrower. It requires stronger case selection, better science on design defect, and clean intake from day one.
The people who were harmed are still harmed. The science linking glyphosate to non-Hodgkin's lymphoma did not change today. The Court decided who gets to weigh that science. Today the answer is the EPA, not a state jury.
What we do with that is up to us.
Contact Michael Stanisci, MassTortMichael
If you are a potential claimant who used Roundup and developed non-Hodgkin's lymphoma, I can help connect you with the right law firm to evaluate your options.
If you are an attorney, I consult end-to-end to improve operations, add meaningful technology to your stack, and grow claimant acquisition across active litigations.
Website: https://www.masstortmichael.com
Instagram: https://www.instagram.com/michaeljstanisci
This is general information only and is not legal advice. Consult qualified counsel for guidance on specific matters.
Copyright © 2026 Michael Stanisci, MassTortMichael. You are encouraged to share or adapt this post within your practice with attribution to #MassTortMichael.
Citations
[1] NPR/Houston Public Media, Supreme Court backs Monsanto in fight over popular weed killer, June 25, 2026: https://www.houstonpublicmedia.org/npr/2026/06/25/g-s1-120233/u-s-supreme-court-backs-monsanto-in-its-fight-against-liability-from-popular-weed-killer/
[2] Supreme Court opinion, Monsanto v. Durnell, No. 24-1068, June 25, 2026: https://www.supremecourt.gov/opinions/25pdf/24-1068_n7ip.pdf
[3] SCOTUSblog docket, Monsanto v. Durnell: https://www.scotusblog.com/cases/monsanto-company-v-durnell/
[4] Chemical & Engineering News, Supreme Court hears Bayer Roundup liability case, April 28, 2026: https://cen.acs.org/environment/pesticides/monsanto-durnell-supreme-court-roundup-glyphosate/104/web/2026/04
[5] Whiteford Law, Roundup at SCOTUS: How Durnell Sets the Settlement Price: https://www.whitefordlaw.com/news-events/client-alert-two-tracks-one-defendant
[6] Supreme Court brief in opposition, No. 25-1042 (Anderson, design defect concession): https://www.supremecourt.gov/DocketPDF/25/25-1042/407959/20260504154817931_25-1042%20Brief%20in%20Opposition.pdf
[7] Drugwatch, Roundup Preemption Case Throws Uncertainty Into Paraquat Settlement Negotiations, February 23, 2026: https://www.drugwatch.com/news/2026/02/23/paraquat-settlement-uncertainty/
[8] The New Lede, Bayer gets boost as US Supreme Court says it will hear Roundup case, January 2026: https://www.thenewlede.org/2026/01/bayer-gets-boost/
[9] SCOTUSblog oral argument report, Justices debate who gets to decide that pesticide labels need a cancer warning, April 28, 2026: https://www.scotusblog.com/2026/04/justices-debate-who-gets-to-decide-that-pesticide-labels-need-a-cancer-warning/
Comments